Literature DB >> 2997082

The restoration of impaired macrophage functions using as immunomodulator the Corynebacterium granulosum-derived P40 fraction.

P Mastroeni, B Bizzini, L Bonina, D Iannello, R A Merendino, D Delfino, M C Berlinghieri, M S Leonardi, A Arena, M C Liberto.   

Abstract

Many microorganisms and compounds of microbial origin exhibit immunomodulatory activities and have been extensively used in immunotherapy of experimental animal tumors and in patients with neoplasia. In this paper we describe the effect of the C. granulosum-derived P40 fraction on the growth and metastatization of the transplantable epithelioma T8 of Guèrin. Moreover, we evaluated the effect of P40 treatment on several depressed macrophage functions of tumor-bearing rats. In particular, the phagocytic and chemotactic activities of such cells were studied, as well as the antiviral intrinsic and extrinsic activities against HSV-1 and the anti-Toxoplasma gondii activity. All these functions were depressed in untreated tumor-bearing rats. Administration of a single intravenous injection of P40 fraction led to the restoration of all depressed macrophage activities to normal values. In particular, the possibility of restoring the antimicrobial activity of macrophages from tumor-bearing rats by treatment with this immunomodulator is of great concern when one considers the increasing incidence of opportunistic infections in immunocompromised hosts. Results are discussed in terms of both the possible mechanism of action of P40 and of its possible target cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997082     DOI: 10.1016/0162-3109(85)90056-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  1 in total

1.  Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone.

Authors:  Katia Mangano; Franca Vergalito; Santa Mammana; Andrea Mariano; Rocco De Pasquale; Antonia Meloscia; Silvia Bartollino; Germano Guerra; Ferdinando Nicoletti; Roberto Di Marco
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.